Tardive dyskinesia and anticholinergic drugs.
The evidence from the literature does not support the notion that psychotropic drugs with central anticholinergic properties (antiparkinsonian drugs, neuroleptics, antidepressants) constitute a risk factor in tardive dyskinesia. Antiparkinsonian drugs tend to produce reversible increases in the severity of dyskinetic movements and can be used as pharmacological probes in the assessment of neuroleptic-induced movement disorders.
D000208:Acute Disease; D000928:Antidepressive Agents / Q000009:adverse effects; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000494:pharmacology; D004347:Drug Interactions; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D010276:Parasympatholytics / Q000009:adverse effects*; D012306:Risk
D000928:Antidepressive Agents; D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D010276:Parasympatholytics